Login to Your Account



Pharma: Other News To Note


Tuesday, November 26, 2013
• Mallinckrodt Inc., of St. Louis, said the FDA extended the review of the new drug application (NDA) for Xartemis XR (oxycodone hydrochloride and acetaminophen) extended-release tablets, previously known as MNK-795, for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription